Healthcare
Ypsomed Holding AG(YPHDF)
Live Price
Offline$354.92
+0.00% today
1Y Change
-15.09%
Window
Jun 23, 2025 → Jun 10, 2026
- Market Cap
- $3.80B
- Revenue Growth
- +36.5%
- EPS Growth
- +11.7%
- Dividend Yield
- 0.8%
Coverage: 247 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ypsomed Holding AG (YPHDF) is a Healthcare stock with a market cap of $3.80B and listed on OTC. The stock last traded around $354.92 and down 15.1% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of +36.5%, EPS growth of +11.7%, a dividend yield of 0.8%. What stands out right now is revenue +36.5%, EPS +11.7%, free cash flow -301.9% with operating margin 18.7% and ROIC 13.7%. The dividend is present but secondary, with a yield around 0.8%. Valuation sits in the middle of the pack at P/E 19.6 and price/sales 4.8. Stock Foundry combines YPHDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+36.5% vs +7.6% peer median
Operating Margin
Near sector median
+18.7% vs +19.4% peer median
P/E
Below sector median
19.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +36.5% and EPS at +11.7%, with operating margin around 18.7%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.8%, which matters if the thesis depends on income as much as growth.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
YPHDF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
YPHDF Max Drawdown
-33.75%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for YPHDF and SPY.
Company Overview
Ypsomed Holding AG
Other OTC
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
- Leadership
- Simon Michel
- IPO Date
- Aug 17, 2022
- Employees
- 2.6k
- Street Address
- Brunnmattstrasse 6
- Mailing
- Burgdorf, 3401
- Region
- Burgdorf, CH
- Reporting Currency
- USD
- Investor Line
- 41 34 424 41 11
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 19.6
- EV/EBITDA
- 14.1
- Price/Sales
- 4.8
- Price/Book
- 4.7
Growth
- Revenue
- +36.5%
- EPS
- +11.7%
- Free Cash Flow
- -301.9%
Profitability
- Gross Margin
- 41.2%
- Operating Margin
- 18.7%
- Net Margin
- 24.6%
- ROE
- 26.9%
- ROIC
- 13.7%
Balance Sheet
- Debt/Equity
- 0.14
- Current Ratio
- 1.47
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.